Carbamate Prodrugs Restrict In Vivo Metabolism and Improve the Pharmacokinetics of Isoniazid

Document Type

Article

Publication Title

ACS Central Science

Abstract

Isoniazid (INH), an important first-line drug in tuberculosis (TB) treatment, faces significant challenges primarily due to hepatotoxicity and peripheral neuropathy as major side effects. These adverse effects often lead to poor patient compliance and treatment dropouts. The INH’s in vivo metabolism is responsible for these adverse effects. INH’s reactive terminal −NH2group is involved in its undesired in vivo metabolic transformations. To address this, we designed and synthesized carbamate-based prodrugs of INH by masking the −NH2group to reduce its metabolic activity. Herein, we report our efforts to develop such prodrugs and their impact on in vivo metabolism and the pharmacokinetic profile of free INH. The ex vivo stability, bioconversion, and in vivo pharmacokinetic profile with detailed metabolite analysis of these prodrugs were determined in mice. The lead prodrug 1d demonstrated enhanced systemic exposure of free INH (1.5-fold, AUC ≈ 3948 ng·h/mL), reduced formation of undesired metabolites, and prolonged half-life (1.3-fold, t1/2≈ 0.88 h) compared to naive INH. This prodrug approach represents a promising strategy for safer and more effective TB therapy, with the potential for less frequent dosing and improved patient compliance.

First Page

1467

Last Page

1480

DOI

10.1021/acscentsci.5c00576

Publication Date

8-27-2025

This document is currently not available here.

Share

COinS